MedTrace Logo

Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19

NCT04828564 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2021-04-02

No results posted yet for this study

Summary

This is a national, multicenter, open-label, randomized, phase II/III trial that evaluates the efficacy and safety of favipiravir and ribavirin in the treatment of patients with confirmed COVID-19 observed within 72 hours. Approximately 100 patients will be randomized in 1:1 ratio and divided into two groups.

Conditions

Interventions

DRUG

Ribavirin Capsules

Ribavirin 200 mg capsules

DRUG

Favipiravir

Favipiravir 200 mg tablets

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    collaborator OTHER

  • Istanbul Umraniye Training and Research Hospital

    collaborator UNKNOWN

  • Koç University

    collaborator OTHER

  • Monitor CRO

    collaborator INDUSTRY

  • The Scientific and Technological Research Council of Turkey

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2021-09-30
Completion
2021-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04828564 on ClinicalTrials.gov